Kolon TissueGene will comprehensively analyze the results of the U.S. Phase 3 clinical trial of TG-C, its osteoarthritis treatment. The topline announcement for the second U.S. Phase 3 trial, originally scheduled for October, has been postponed to December.

As of 9:49 a.m. on the 24th, Kolon TissueGene's share price was trading at 19,570 won, down 5.69% from the previous day and falling below the 20,000-won level.

■ Comprehensive Analysis Linking First and Second Phase 3 Trials

Kolon TissueGene held an online shareholder meeting on the 11th, explaining the additional analysis and ongoing review of the TG-C first U.S. Phase 3 topline results disclosed last month, as well as its future strategy.

The company plans to closely examine the results of the first Phase 3 trial while also reviewing the results of the second Phase 3 trial together, conducting a comprehensive analysis. Accordingly, the timing of the second topline announcement, originally scheduled for October, has been adjusted to December. This is interpreted as a decision to conduct a more in-depth evaluation by linking the additional analysis of the first trial results with the second trial results.

TG-C is an osteoarthritis treatment under development by Kolon TissueGene, and the progress and key metrics of its U.S. Phase 3 trials are regarded as critical variables that will determine the company's future business strategy.

■ Market Focuses on Detailed Analysis Results and Follow-up Strategy

With the schedule for the second topline announcement delayed, the market is expected to remain focused on the detailed analysis results to be disclosed and the company's follow-up strategy. In particular, what findings emerge from the additional analysis of the first trial results, and how the evaluation of efficacy and safety will be summarized when combined with the second trial results, are likely to be key points.

However, as clinical trials may see changes in schedules and development strategies depending on detailed data analysis and consultations with regulatory authorities, it is necessary to check the company's official announcements and disclosures going forward.

[This article was written with AI assistance. It is not intended to recommend investment in or the purchase or sale of any specific stock. Share prices of biotech and pharmaceutical companies can exhibit high volatility depending on clinical trial results, development timelines, and regulatory decisions. Investors should carefully review the company's official disclosures and clinical trial-related announcements and make prudent decisions; the final responsibility for investment lies with the investor.]